AACR 2024 | Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good
• 9 Apr 2024
Zinaida Good, PhD, Stanford University, Stanford, CA, comments on the findings of using a lineage tracing approach to define responding CAR T-cells in patients with large B-cell lymphoma (LBCL). Identifying which cell populations expand during manufacturing and mediate therapeutic efficacy may allow for a greater ability to manufacture CAR T-cells that will improve patient outcomes. Dr Good also briefly outlines the impact of the presence of regulatory T-cells (Tregs). This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
